l-carnitina 3000 efectos secundarios Suplementación Con l carnitina quemador de grasa
Description
4.88 1.78 mIU/ml, p=0.009) at the end of the intervention
Massima purezza e rapido assorbimento
doi: 10.1016/j.pneurobio.2011.06.003
Conclusions The favourable outcomes of this retrospective study on ALC treatment in FMS represent a pivotal advancement in exploring a novel pharmacological approach centred on well-tolerated molecules, particularly beneficial for patients requiring long-term therapies
